ReviewClinical and experimental medicine2025
Function of p53 in angiogenesis and oxidative stress in rheumatoid arthritis.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molecular mechanisms of herbal medicines and bioactive compounds in rheumatoid arthritis: a comprehensive network pharmacology perspective.Molecular biology reports · 2026Review
- Natural Bioactive Compounds in Rheumatoid Arthritis: Experimental Evidence from Adjuvant Arthritis Model Supporting Combination Strategies with Methotrexate.International journal of molecular sciences · 2026Review
- Disturbances in Central Sensitization Are Associated with Disease Severity and Alterations in Gene Expression Measured in the Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2026Article
- Blood and lymphatic vascular remodeling in intervertebral disc degeneration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a complex disorder that involves the immune system, inflammation, and the growth of abnormal tissue in the joints, causing damage. The development of RA is regulated by important factors such as inflammatory cytokines, active angiogenesis, and oxidative stress, which promote the process of autoimmunity, chronic inflammation, and tissue destruction. Recent studies have shown that activation of p53, a protein that suppresses the growth of tumors, is an ongoing process that commonly occurs during inflammation. This activation contributes to regulating and controlling normal inflammatory responses. Functional mutations in the p53 gene have been detected in the synovial tissue in individuals diagnosed with RA, especially those with severe and destructive illness. These mutations may occur due to persistent inflammation caused by reactive oxygen species (ROS), leading to changes in the genetic material. The overall absence of the p53 leads to elevated hypoxia-inducible factor 1 (HIF-1) alpha subunit levels and enhances HIF-1α-mediated activation of the vascular endothelial growth factor (VEGF) gene in low-oxygen conditions, thereby promoting neovascularization. Furthermore, p53 modulates ROS production via nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4), with wild-type p53 inhibiting NOX4 induction, ROS generation, and cellular migration, whereas mutant-p53 enhances NOX4 expression, ROS production and promotes cell migration. This review addresses the importance of p53 in the processes of NADPH oxidase and angiogenesis, both of which are important in developing RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.